Abbott India

Drug firm Abbott has launched a pacemaker in India for the treatment of patients with slow heart rhythms. Abbott has introduced AVEIR VR single-chamber ventricular leadless pacemaker which has been approved by the Central Drugs Standard Control Organisation, the company said in a statement on Friday. The product has also been approved by the US Food and Drug Administration (USFDA). "The AVEIR VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options," said Ajay Singh Chauhan, General Manager for Abbott's Cardiac Rhythm Management business in India, Southeast Asia, HK, Taiwan & Korea. People who experience slower-than-normal heart rhythm may receive a pacemaker to deliver pulses of electricity to trigger the heart to beat properly. Balbir Singh, Chairman Cardiology, Max Superspeciality Hospital said, "Leadless pacemakers address known complications associated with ...

Pentids are widely prescribed for treating bacterial infections of the respiratory tract, throat, lungs, nose, skin, and sexually transmitted diseases like syphilis

The uptick in the pharma company's stock price came after it posted a healthy set of numbers in the June quarter of financial year 2025 (Q1FY25).

Drug firm Abbott India on Wednesday said its net profit increased by 13 per cent year on year to Rs 328 crore for the first quarter ended June 30, 2024. The company reported a net profit of Rs 290 crore in the April-June quarter of last fiscal. Total income rose to Rs 1,625 crore for the period under review as against Rs 1,535 crore in the June quarter of FY24, Abbott India said in a regulatory filing. Shares of the company on Wednesday ended 1.29 per cent up at Rs 28,159.95 apiece on the BSE.

Abbott India's profit jumped 24.1 per cent to Rs 287.1 crore in the March quarter of FY24 (Q4FY24), from Rs 231.4 crore in the March quarter of FY23 (Q4FY23)

The drugmaker's revenue from operations increased to Rs 1,439 crore, a 7 per cent increase from the Rs 1,343 crore recorded in Q4 FY23

Technical outlook on stocks with high rollover to May series: Keep a tab on these key support and resistance levels while trading in these F&O stocks.

The company's Year-on-Year revenue growth of 8.3% exceeded expectations and its top line was aided by a product mix led by therapies

Firm's revenues were in line with estimates and operational parameters better than expected

The company, which makes popular antacid medicine Digene, said its profit rose to 3.11 billion rupees ($37.5 million) from 2.47 billion rupees a year earlier

The two laxative brands together have estimated annual sales of $70 million in India, healthcare data firm Pharmarack says

The state authorities have given Abbott seven days to respond to the notice to defend its position

In its letter, the DCGI warned that Digene may be unsafe and its use may result in adverse reaction

India's drugs regulator issues advisory against use; company says there is no 'health concern'

The company has reported a double-digit growth in its revenue for the past three quarters, led by falling operating expenses and steady sales

Stocks to watch today: From Hindustan Unilever to Wipro, here are top stocks to watch in Thursday's trading session

These 5 mid-cap stocks may rise up to 20 per cent, as technical charts reveal positive breakouts

Margins to remain healthy on the back of cost-saving measures

A portfolio of richly valued RoE stocks is expected to outperform the broader market over the longer term.

Analysts expect double-digit growth for pharma major even if Q1 disappointed